Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy.
Youyou LiJing LiuYimei ChenRalph R WeichselbaumWenbin LinPublished in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
The recent discovery of copper-mediated and mitochondrion-dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death for cancer therapy. Here the design of a core-shell nanoparticle, CuP/Er, for the co-delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis is reported. The anti-Warburg effect of Er sensitizes tumor cells to Cu-mediated cuproptosis, leading to irreparable mitochondrial damage by depleting glutathione and enhancing lipid peroxidation. CuP/Er induces strong immunogenic cell death, enhances antigen presentation, and upregulates programmed death-ligand 1 expression. Consequently, CuP/Er promotes proliferation and infiltration of T cells, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple-negative breast cancer and prevent tumor metastasis. This study suggests a unique opportunity to synergize cuproptosis and ferroptosis with combination therapy nanoparticles to elicit strong antitumor effects and potentiate current cancer immunotherapies.
Keyphrases
- cell death
- endoplasmic reticulum
- estrogen receptor
- combination therapy
- cancer therapy
- breast cancer cells
- cell cycle arrest
- oxidative stress
- poor prognosis
- signaling pathway
- drug delivery
- small molecule
- high throughput
- case report
- radiation therapy
- machine learning
- squamous cell
- induced apoptosis
- long non coding rna
- endoplasmic reticulum stress
- binding protein
- pi k akt